Preoperative Radiochemotherapy in Rectal Cancer: Is There an Impact of Oxaliplatin on Pathologic Complete Response and Survival Rates under “Real World“ Conditions?
Round 1
Reviewer 1 Report
This is a retrospective analysis, “real world data” over a consecutive period of 15 years on the patterns of nRCT in LARC patients, to address the question “is the additional administration of oxaliplatin during nRCT beneficial in terms of pathologic complete remission (pCR), disease-free survival (DFS), and overall survival 71 (OS)?”. In this study, 228 patients after the propensity score matching analyses (PSM), 114 pts for each group of fluorouracil/ capecitabine-group and fluorouracil/ capecitabine plus oxaliplatin-group, were included. Generally, it is well designed and valuable study with the available clinical data. The results are clear, and the statistical analyses of data and the conclusion are appropriate and reasonable. In this manuscript, other related reports have also been reviewed and discussed. Overall, it is an interesting work, the information provided in this study would be beneficial to improving clinical therapy at least for LARC patients.
This is no more comment on this manuscript.
Reviewer 2 Report
In my opinion it is a relevant article. Study is well designed and executed. Conclusions are sound and are backed by the data. It can be published in the current form.
